Home › Obstructive Sleep Apnea › NCT07220525

Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation

Who can join

Ages 21 and older · All sexes

Inclusion Criteria:

* Are age 21 years or older
* Have a HGNS device implanted for obstructive sleep apnea and followed up at UCSF Health
* Are willing to abstain from using the upper airway stimulation device for no more than two consecutive days as instructed over the 14-day trial period
* Able and willing to provide written informed consent

Exclusion Criteria:

* Currently pregnant or trying to get pregnant
* Are currently taking class 1 or 3 anti-arrhythmic medications
* Have a history of permanent AF or expected to have continuous AF throughout the study period
* Have congenital heart disease
* Ventricular pacing \>40%
* Are unable to read or sign to provide informed consent

About the study

Whereas the available evidence mostly supports chronic sleep disruption as a risk factor for incident AF, less is known about the near-term risk of a discrete atrial fibrillation (AF) episode following a night of disrupted or poor-quality sleep. This prospective, randomized, case-crossover study aims to examine the acute effects of sleep disruption on clinically relevant cardiac ectopy pertinent to AF.

What is being tested

• HGNS Use Randomized Instructions (device)

Sponsor: University of California, San Francisco · Participants: 100 · Started: Dec 15, 2025

Contact the study team

• Hannah Oo, BS · Phone: 415-476-4999
• Bella Peña, BA · Phone: 415-502-3053

Official record on ClinicalTrials.gov — NCT07220525

Locations in the U.S.

Conditions

• Obstructive Sleep Apnea
• Ventricular Premature Complexes
• Atrial Fibrillation
• Sleep Apnea

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.